Microba Life Sciences Limited (ASX:MAP)
Australia
· Delayed Price · Currency is AUD 0.0820
0.00 (0.00%)
At close: Mar 6, 2026
Microba Life Sciences Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2019 |
| Revenue | 14.9 | 15.67 | 12.09 | 5.42 | 4.69 | 3.73 | Upgrade
|
| Revenue Growth (YoY) | -11.81% | 29.60% | 123.06% | 15.60% | 25.62% | 28.31% | Upgrade
|
| Cost of Revenue | 7.93 | 8.23 | 6.18 | 2.74 | 2.32 | 1.69 | Upgrade
|
| Gross Profit | 6.97 | 7.44 | 5.91 | 2.68 | 2.37 | 2.04 | Upgrade
|
| Selling, General & Admin | 22.18 | 22.52 | 16.01 | 10.18 | 10.27 | 7.31 | Upgrade
|
| Research & Development | 1.54 | 2.01 | 10.84 | 9.34 | 5.38 | 2.1 | Upgrade
|
| Other Operating Expenses | 3.3 | 3.09 | 2.03 | 1.75 | 1.44 | 0.93 | Upgrade
|
| Operating Expenses | 31.48 | 32.05 | 31.74 | 22.91 | 18.64 | 11.56 | Upgrade
|
| Operating Income | -24.51 | -24.61 | -25.84 | -20.23 | -16.27 | -9.52 | Upgrade
|
| Interest Expense | -0.18 | -0.18 | -0.07 | -0.06 | -0.06 | -0.02 | Upgrade
|
| Interest & Investment Income | 0.43 | 0.58 | 1 | 0.88 | 0.05 | 0.1 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.08 | 1.76 | 0.1 | 0.37 | 0.49 | -0.05 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.93 | 2.93 | 5.82 | 6.37 | 4.32 | 1.97 | Upgrade
|
| EBT Excluding Unusual Items | -21.25 | -19.52 | -18.98 | -12.67 | -11.46 | -7.52 | Upgrade
|
| Merger & Restructuring Charges | - | - | -1.01 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.02 | - | - | - | - | - | Upgrade
|
| Other Unusual Items | 2.05 | 4.47 | - | - | - | - | Upgrade
|
| Pretax Income | -19.97 | -15.05 | -19.99 | -12.67 | -11.46 | -7.52 | Upgrade
|
| Income Tax Expense | -0.22 | -0.11 | -0.05 | 0.01 | 0.01 | - | Upgrade
|
| Net Income | -19.75 | -14.94 | -19.94 | -12.68 | -11.47 | -7.52 | Upgrade
|
| Net Income to Common | -19.75 | -14.94 | -19.94 | -12.68 | -11.47 | -7.52 | Upgrade
|
| Shares Outstanding (Basic) | 518 | 448 | 410 | 314 | 223 | 183 | Upgrade
|
| Shares Outstanding (Diluted) | 518 | 448 | 410 | 314 | 223 | 183 | Upgrade
|
| Shares Change (YoY) | 15.66% | 9.40% | 30.42% | 40.87% | 21.61% | 17.01% | Upgrade
|
| EPS (Basic) | -0.04 | -0.03 | -0.05 | -0.04 | -0.05 | -0.04 | Upgrade
|
| EPS (Diluted) | -0.04 | -0.03 | -0.05 | -0.04 | -0.05 | -0.04 | Upgrade
|
| Free Cash Flow | -15.38 | -12.34 | -17.05 | -12.94 | -12.08 | -7.43 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.03 | -0.04 | -0.04 | -0.05 | -0.04 | Upgrade
|
| Gross Margin | 46.77% | 47.49% | 48.84% | 49.41% | 50.46% | 54.61% | Upgrade
|
| Operating Margin | -164.43% | -157.05% | -213.71% | -373.24% | -347.05% | -255.09% | Upgrade
|
| Profit Margin | -132.53% | -95.34% | -164.92% | -233.95% | -244.64% | -201.58% | Upgrade
|
| Free Cash Flow Margin | -103.22% | -78.75% | -141.06% | -238.82% | -257.75% | -199.04% | Upgrade
|
| EBITDA | -23.06 | -22.47 | -23.67 | -19.09 | -15.56 | -8.95 | Upgrade
|
| EBITDA Margin | -154.71% | -143.43% | -195.80% | - | - | -239.87% | Upgrade
|
| D&A For EBITDA | 1.45 | 2.13 | 2.16 | 1.14 | 0.72 | 0.57 | Upgrade
|
| EBIT | -24.51 | -24.61 | -25.84 | -20.23 | -16.27 | -9.52 | Upgrade
|
| EBIT Margin | -164.43% | -157.05% | -213.71% | - | - | -255.09% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.